Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Key updates from ASCO GI 2021

Philippe Merle • 14 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Liver Cancer Antibodies Atezolizumab Bevacizumab Sorafenib
IMbrave150

Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, updates on key trials that wil be presented at this years upcoming American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the updated overall survival results of the IMbrave150 study (NCT03434379), evaluating atezolizumab and bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Philippe Merle

2:09
KEYNOTE-240: pembrolizumab in advanced HCC
Philippe Merle • 14 Jan 2021
1:16
Future directions & unmet needs in HCC
Philippe Merle • 14 Jan 2021

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals